These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
430 related articles for article (PubMed ID: 18669866)
41. KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials. Kim SY; Shim EK; Yeo HY; Baek JY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Jung KH; Chang HJ Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):201-7. PubMed ID: 22672749 [TBL] [Abstract][Full Text] [Related]
42. Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients. Lupini L; Bassi C; Mlcochova J; Musa G; Russo M; Vychytilova-Faltejskova P; Svoboda M; Sabbioni S; Nemecek R; Slaby O; Negrini M BMC Cancer; 2015 Oct; 15():808. PubMed ID: 26508446 [TBL] [Abstract][Full Text] [Related]
43. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective. Blank PR; Moch H; Szucs TD; Schwenkglenks M Clin Cancer Res; 2011 Oct; 17(19):6338-46. PubMed ID: 21807639 [TBL] [Abstract][Full Text] [Related]
44. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Garm Spindler KL; Pallisgaard N; Rasmussen AA; Lindebjerg J; Andersen RF; Crüger D; Jakobsen A Ann Oncol; 2009 May; 20(5):879-84. PubMed ID: 19179548 [TBL] [Abstract][Full Text] [Related]
45. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer. Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995 [TBL] [Abstract][Full Text] [Related]
46. Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study. Ulivi P; Capelli L; Valgiusti M; Zoli W; Scarpi E; Chiadini E; Rosetti P; Bravaccini S; Calistri D; Saragoni L; Casadei Gardini A; Ragazzini A; Frassineti GL; Amadori D; Passardi A J Transl Med; 2012 May; 10():87. PubMed ID: 22569004 [TBL] [Abstract][Full Text] [Related]
47. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. Bardelli A; Siena S J Clin Oncol; 2010 Mar; 28(7):1254-61. PubMed ID: 20100961 [TBL] [Abstract][Full Text] [Related]
48. EGFR L2 domain mutation is not correlated with resistance to cetuximab in metastatic colorectal cancer patients. Ito Y; Yamada Y; Asada K; Ushijima T; Iwasa S; Kato K; Hamaguchi T; Shimada Y J Cancer Res Clin Oncol; 2013 Aug; 139(8):1391-6. PubMed ID: 23722667 [TBL] [Abstract][Full Text] [Related]
49. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288 [TBL] [Abstract][Full Text] [Related]
50. EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients. Li YH; Wang F; Shen L; Deng YM; Shao Q; Feng F; An X; Wang FH; Wang ZQ; Xu RH; Shao JY Clin Cancer Res; 2011 Jan; 17(2):382-90. PubMed ID: 20884623 [TBL] [Abstract][Full Text] [Related]
51. Xu JM; Wang Y; Wang YL; Wang Y; Liu T; Ni M; Li MS; Lin L; Ge FJ; Gong C; Gu JY; Jia R; Wang HF; Chen YL; Liu RR; Zhao CH; Tan ZL; Jin Y; Zhu YP; Ogino S; Qian ZR Clin Cancer Res; 2017 Aug; 23(16):4602-4616. PubMed ID: 28424201 [No Abstract] [Full Text] [Related]
52. Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models. Belli V; Matrone N; Napolitano S; Migliardi G; Cottino F; Bertotti A; Trusolino L; Martinelli E; Morgillo F; Ciardiello D; De Falco V; Giunta EF; Bracale U; Ciardiello F; Troiani T J Exp Clin Cancer Res; 2019 Jun; 38(1):236. PubMed ID: 31164152 [TBL] [Abstract][Full Text] [Related]
53. PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy. Barbareschi M; Cuorvo LV; Girlando S; Bragantini E; Eccher C; Leonardi E; Ferro A; Caldara A; Triolo R; Cantaloni C; Decarli N; Galligioni E; Dalla Palma P Virchows Arch; 2012 Aug; 461(2):129-39. PubMed ID: 22744290 [TBL] [Abstract][Full Text] [Related]
54. Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study. Razis E; Briasoulis E; Vrettou E; Skarlos DV; Papamichael D; Kostopoulos I; Samantas E; Xanthakis I; Bobos M; Galanidi E; Bai M; Gikonti I; Koukouma A; Kafiri G; Papakostas P; Kalogeras KT; Kosmidis P; Fountzilas G BMC Cancer; 2008 Aug; 8():234. PubMed ID: 18700047 [TBL] [Abstract][Full Text] [Related]
55. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Dahabreh IJ; Terasawa T; Castaldi PJ; Trikalinos TA Ann Intern Med; 2011 Jan; 154(1):37-49. PubMed ID: 21200037 [TBL] [Abstract][Full Text] [Related]
56. A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients. Bonin S; Donada M; Bussolati G; Nardon E; Annaratone L; Pichler M; Chiaravalli AM; Capella C; Hoefler G; Stanta G Tumour Biol; 2016 Jun; 37(6):7295-303. PubMed ID: 26666825 [TBL] [Abstract][Full Text] [Related]
57. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study. Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966 [TBL] [Abstract][Full Text] [Related]
58. KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease. Tessitore A; Bruera G; Mastroiaco V; Cannita K; Cortellini A; Cocciolone V; Dal Mas A; Calvisi G; Zazzeroni F; Ficorella C; Ricevuto E; Alesse E Hum Pathol; 2018 Apr; 74():178-182. PubMed ID: 29409955 [TBL] [Abstract][Full Text] [Related]
59. Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients. Zlobec I; Molinari F; Kovac M; Bihl MP; Altermatt HJ; Diebold J; Frick H; Germer M; Horcic M; Montani M; Singer G; Yurtsever H; Zettl A; Terracciano L; Mazzucchelli L; Saletti P; Frattini M; Heinimann K; Lugli A Br J Cancer; 2010 Jan; 102(1):151-61. PubMed ID: 19935791 [TBL] [Abstract][Full Text] [Related]
60. New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS? Bronte G; Silvestris N; Castiglia M; Galvano A; Passiglia F; Sortino G; Cicero G; Rolfo C; Peeters M; Bazan V; Fanale D; Giordano A; Russo A Oncotarget; 2015 Sep; 6(28):24780-96. PubMed ID: 26318427 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]